Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma
Yosuke KamideKyoichi KairaTakuya WatanabeShiko KuribayashiAtsushi OzawaYasuhiko KogaAkihiro OnoNoriaki SunagaTakeshi HisadaTetsunari OyamaMasanobu Yamada
Author information
JOURNALS OPEN ACCESS

2015 Volume 54 Issue 22 Pages 2905-2909

Details
Abstract

A 55-year-old woman was diagnosed with a tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) rearrangement-positive lung adenocarcinoma and treated with chemotherapy consisting of crizotinib, a tyrosine kinase inhibitor of ALK, as second-line chemotherapy. However, the size of the metastatic adrenal lesion increased, and the patient died due to multiple organ failure. An autopsy report revealed that the metastatic lesion of the adrenal tumor was ALK rearrangement-positive pleomorphic carcinoma. The epithelial-mesenchymal transition (EMT) marker vimentin was immunohistochemically positive in both the lung and adrenal lesions. The present case report suggests the possibility of transformation into pleomorphic carcinoma as a result of EMT in patients with ALK rearrangement-positive lung cancer.

Information related to the author
© 2015 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top